Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
Stock Information for Protalix BioTherapeutics Inc. (DE)
Loading
Please wait while we load your information from QuoteMedia.